P
ancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer death in the United States, proving fatal to nearly all who are diagnosed (1) . PDA is thought to arise from ductal precursor lesions termed pancreatic intraepithelial neoplasia (PanIN), which accumulate mutations and become progressively dysplastic, finally forming metastatic tumors. Activation of the KRAS proto-oncogene, which is seen in almost all PDA cases, occurs in many early PanINs and may represent an initiating event (1) .
PDA has been modeled in mouse by use of a Cre-dependent activated Kras allele, Kras loxP-STOP-loxP-G12D (henceforth, Kras G12D ), which induces mouse PanIN lesions (mPanINs) similar to those seen in humans (2) (3) (4) . Interestingly, although previous studies used Pdx1Cre or Ptf1a
Cre drivers to activate Kras G12D throughout the pancreas, mPanINs formed only focally, and most of the organ appeared normal (2, 3) . This suggests that only a subset of cells in the pancreas can be transformed by activated Kras, although the basis of this specificity remains unknown. Additional signaling pathways that may promote Kras-mediated transformation are active in human and mouse PanINs, including the Notch pathway (1, 2) . Notch is of particular interest given its importance to embryonic pancreas development (5) , and its involvement in phenotypic plasticity of adult exocrine cells (6, 7) . In turn, exocrine cell plasticity is likely relevant to the long-standing question of where pancreatic cancer originates.
Under certain circumstances, including exposure to the EGF receptor ligand TGF-␣, acinar cells can assume duct-like characteristics (6, 8, 9) . Importantly, TGF-␣-induced acinar-to-duct conversion requires Notch activity (6) . Ras proteins are downstream effectors of the EGF receptor, and overexpressing activated Kras in acinar cells also causes ductal metaplasia and tumors of mixed acinar/ductal character (10, 11) . Overexpression of activated Kras in duct cells, by contrast, does not produce PanINs or other dysplastic lesions (12) . Conversion of acinar cells to a duct-like phenotype may therefore be an important first step in pancreatic tumorigenesis.
This hypothesis receives support from several recent studies, using Cre-dependent endogenous Kras G12D or Kras G12V alleles. First, mPanIN formation in young Kras G12D ;Ptf1a
Cre mice is associated with acinar-ductal metaplasia, and similar metaplastic lesions can be found associated with human PanINs (13) . Second, activation of Kras G12D specifically in acinar precursors, by using NestinCre, produces mPanINs identical to those seen with Pdx1Cre and Ptf1a Cre (14) . Finally, and most critically, activation of Kras G12V in adult acinar and centroacinar cells (CACs) leads to acinar-ductal metaplasia and mPanIN formation after experimentally induced pancreatitis (15) . Experimental pancreatitis activates the Notch pathway (7, 16, 17) , and this pathway also appears to be activated during metaplasia induced by Kras G12V (15) . As this study involved activation in both acini and CACs, however, it remains unclear which cell type is the actual mPanIN cell of origin. Furthermore, although Notch promotes acinar-ductal metaplasia in vitro, its contribution to pancreatic cancer initiation remains unknown.
Here, we test the hypothesis that Notch activation confers sensitivity to Kras G12D , and that this cooperative interaction drives conversion of acinar cells to preinvasive PanIN lesions. We find that coactivation of Notch and Kras, by using a relatively nonspecific Pdx1CreERT driver, dramatically increases mPanIN formation compared with Kras activation alone. Furthermore, we find that fully differentiated adult acinar cells are able to form mPanIN lesions after Kras G12D activation, and that coactivation of Notch accelerates this process. Notch and Kras coactivation causes rapid reprogramming of acinar cells to a duct-like phenotype, suggesting an explanation for how precursors of a ductal cancer can originate from nonductal differentiated cells. (19) . On tamoxifen (TM) administration in utero, a dose-dependent subset of Pdx1 ϩ progenitor cells undergoes recombination, whereas nonrecombined cells contribute to normal pancreatic function. Pregnant females from crosses involving all three alleles (Kras G12D , Rosa26 NIC , and Pdx1CreERT) were administered 1.5 mg TM at embryonic day 10.5, a dose producing recombination in 25-50% of duct, acinar and islet cells (data not shown).
Results

Notch
The resulting offspring were killed at 1 month of age and subjected to histological analysis ( Fig. 1 A-F) . Rosa26 NIC ;Pdx1CreERT pancreata contained undifferentiated epithelia similar to those observed in Rosa26 NIC ;Pdx1Cre (18), albeit affecting much less of the organ ( Fig. 1 A and D) . As expected, pancreata of Kras G12D ;Pdx1CreERT mice exhibited focal mPanIN formation ( Fig. 1 B and E) , similar to that seen in Kras G12D ;Pdx1Cre (2, 3). When both Notch and Kras were activated (Kras G12D ;Rosa26 NIC ;Pdx1CreERT), however, nearly the entire organ was overtaken by PanIN-like epithelium ( Fig. 1  C and F) . These results suggest that by blocking differentiation, activated Notch sensitizes pancreatic progenitor cells to Kras. The severity of the phenotype, however, precluded quantitative analysis.
When we analyzed offspring of mothers that did not receive TM, we found that a low level of TM-independent recombination induced numerous focal mPanIN lesions in Kras G12D ; Rosa26 NIC ;Pdx1CreERT mice (Fig. 1I) . By contrast, few or no abnormalities were found in untreated Kras-only or Notch-only pancreata ( Fig. 1 G and H (Fig. 1J) .
Like mPanINs described previously (2, 3), those found in both Kras G12D ;Pdx1CreERT and Kras G12D ;Rosa26 NIC ;Pdx1CreERT mice express the duct marker cytokeratin-19 (CK19) and produce periodic acid-Schiff (PAS)-reactive mucins (see supporting information (SI) Fig. S1 A-F G12D ;Pdx1Cre pancreata, we noted frequent areas of apparent acinar-ductal metaplasia, including cells coexpressing acinar and duct markers, sometimes adjacent to mPanINs (Fig. S2) . As with mPanINs themselves, these lesions occur more frequently when Rosa26 NIC is coexpressed with Kras G12D (Fig. S3A ). Similar findings in Kras G12D ;Ptf1a
Cre mice, and in human specimens, suggest that metaplasia may be an early step in the conversion of acini to PanINs (13) .
To determine whether PanINs can arise from differentiated acinar cells, we used transgenic mice in which the acinar-specific Elastase1 promoter drives expression of CreERT. This ElaCreERT line has been extensively documented to induce acinar-specific recombination, excluding duct or centroacinar cells (9, 20, 21) . 
isolated mPanIN lesions (E, arrow). Broad coactivation of both alleles results in almost complete replacement of normal exocrine tissue by mPanIN-like epithelium (C and F). Focal mosaic activation of NotchIC or Kras alone, in the absence of TM, produces no or few abnormalities (G and H), whereas focal coactivation of both alleles induces numerous mPanIN lesions (I, arrow). Also indicated are normal ducts (du) and islets (is). (Magnification: A-C 100ϫ, D-F 400ϫ, G-I 200ϫ.) (J) Stripchart of mPanIN initiation indices for individual TM-untreated Pdx1CreERT mice, expressing activated
Notch1 (Notch) and/or Kras G12D (Kras), at indicated ages. P-values (by t test): * , P Ͻ 0.05, ** , P Ͻ 0.01.
Adult (6-weeks-old) Kras G12D ;ElaCreERT mice were given 5 mg TM, inducing recombination in Ϸ50% of acinar cells, and killed 1, 2, or 10 weeks thereafter (i.e., 7 weeks, 2 months, or 4 months of age). Like Pdx1CreERT, ElaCreERT confers a low level of TM-independent recombination (20); we therefore examined additional 2-and 4-month-old mice that did not receive TM. Although most mice did not exhibit gross pancreatic abnormalities, regardless of TM treatment, histological analysis revealed that they often contained mPanIN lesions identical to those observed with general pancreatic Cre drivers (Fig. 2 , and see below). In total, at least one mPanIN was found in 12/33 Kras G12D ;ElaCreERT pancreata examined, and the likelihood of finding mPanINs increased with the age of the mouse (P Ͻ 0.005 by 2 test for trend). Whereas most mPanIN lesions found were low-grade (mPanIN-1), more advanced mPanIN-2 and mPanIN-3 lesions were found in 6/33 (18%) and 1/33 (3%) of Kras G12D ;ElaCreERT pancreata, respectively. These results indicate that mature acinar cells are a potential source of PanINs, and possibly for ''ductal'' adenocarcinoma as well.
Notch Activation Sensitizes Acinar Cells to Kras-Driven mPanIN Formation and Progression. Similar to Kras G12D ;Pdx1Cre, the vast majority of acinar cells are unaffected in Kras G12D ;ElaCreERT mice, with or without TM treatment. As Notch and Kras synergize after activation by PdxCreERT, we asked whether they also synergize in adult acinar cells. In parallel with the Kras G12D ;ElaCreERT experiments described above, littermates also inheriting Rosa26 NIC were administered 5 mg of TM at 6 weeks of age, and killed 1, 2, or 10 weeks later. Although activation of Rosa26 NIC alone in acini had no visible effect ( Fig.  3B and see below) , it did induce robust expression of the Notch target genes Hes1 and HeyL (Fig. S4) . By contrast, coactivation of Rosa26 NIC and Kras G12D caused widespread mPanIN formation, exceeding that seen with Kras G12D alone (Fig. 3 C-E) . Similar synergy was observed with respect to acinar-ductal metaplasia, for which Notch alone was also ineffective (Fig.  S3B) . Notch/Kras coactivation did not result in greater induction of Hes1 or HeyL than Notch alone (Fig. S4) , suggesting that the synergy between these pathways is unlikely to occur at the level of immediate Notch target genes.
The same relationship was observed in TM-untreated mice ( Fig. S5 A and B) . For reasons as yet unknown, we found that untreated Kras G12D ;ElaCreERT mice exhibited more mPanINs than TM-treated mice at the same age, although the synergy with Rosa26 NIC remains dramatic and robust. By contrast, the apparently greater number of mPanINs seen in untreated Kras G12D ;Rosa26 NIC -expressing mice, compared to those receiving TM (Fig. 3E and Fig. S5A ), likely reflects the fact that untreated pancreata retain more normal exocrine tissue (Fig. S5  C and D) . Individual lesions are therefore more easily scored than in TM-treated mice, where the lack of normal tissue makes separate lesions hard to distinguish.
Previous studies of Kras G12D ;Pdx1Cre mice indicate that highergrade mPanIN-2 and mPanIN-3 lesions are much rarer than mPanIN-1, although they become more common as the overall lesion burden increases with age (2). To determine whether Notch affects this process, we developed an mPanIN progression metric based on observation by a blinded pathologist (L.E.), and weighted according to increasing lesion stage (see Materials and Methods). In every ElaCreERT experimental group (i.e., separated by age and TM treatment), the progression index was significantly higher with Notch and Kras together than with activated Kras alone (P Ͻ 0.05 by Wilcoxon test). Although this suggested that Notch promotes mPanIN progression, it was also possible that, by enhancing mPanIN initiation, Notch activation would make it likelier to encounter rare advanced lesions even if the progression rate were unchanged. This would predict that the progression index should correlate with overall mPanIN number, irregardless of Rosa26 NIC status. As the individual experimental groups were too small to model separately the effects of lesion number and genotype, we pooled all ElaCre-ERT samples that contained at least one mPanIN and compared the effects of overall mPanIN number and genotype on progression index (Fig. S6) . We developed a general linear model, in which progression index was influenced separately by mPanIN number and Rosa26 NIC genotype (see Materials and Methods), and found that Rosa26 NIC activation significantly correlated with increased progression (P Ͻ 5 ϫ 10 Ϫ6 , by F-test). Similar results were obtained by analysis of our Pdx1CreERT samples, either separately or pooled with ElaCreERT, suggesting that Notch promotes both mPanIN initiation and progression.
Formation of PanINs from Acinar Cells via Reprogramming to a Ductal
Phenotype. PanIN and PDA, in humans and mice, typically look like ducts and express duct-specific markers. Nevertheless, our results indicate that mPanINs can arise from mature acinar cells, implying that their formation involves a switch from acinar to ductal differentiation programs. To follow this switch, we examined ElaCreERT mice two weeks following tamoxifen treatment, at which time Kras activation alone has had little or no detectable effect, whereas Notch/Kras coactivation has induced widespread metaplasia (Fig. 3E and Fig. S3B ). As GFP expression marks cells that have undergone Rosa26 NIC activation (18), we performed coimmunofluorescence to monitor expression of acinar and ductal markers in cells expressing activated Notch. As expected, Cre-negative pancreata exhibit no detectable GFP (Fig. 4 A-D and M-P) . Also as expected, TM-treated Rosa26 NIC ;ElaCreERT pancreata exhibit widespread Rosa26 NIC activation, indicated by GFP expression (Fig. 4 E and Q) . Nonetheless, these cells retain a normal acinar differentiation program: they express the digestive enzyme amylase and the transcription factor Ptf1a (Figs. 4 F and R) , a regulator of acinar gene expression (5), and they are negative for the duct marker CK19 (Fig. 4 G and S) . Therefore, Notch activation alone does not detectably perturb the differentiation state of mature acinar cells. Following coactivation of Notch and Kras, however, nearly all GFP-expressing cells undergo reprogramming to a duct-like phenotype, including loss of amylase and Ptf1a expression (Fig.  4 J and V) and up-regulation of CK19 (Fig. 4 K and W) . A similar reprogramming event must occur in Kras G12D ;ElaCreERT mice, as the PanIN lesions that form in these pancreata are positive for CK19 (Fig. 2D ) and negative for amylase and Ptf1a (data not shown), but the efficiency of conversion is much higher when Notch is activated together with Kras. These data implicate the reprogramming of acinar cells, including down-regulation of the acinar regulator Ptf1a, in the formation of ductal lesions and tumors from a nonductal cell type.
Discussion
Notch is a critical negative regulator of progenitor cell differentiation in the embryonic pancreas, and its up-regulation in PanINs and pancreatic cancer suggests that it represses the differentiation of tumor-initiating cells (2, 6, 13) . This possibility is particularly compelling given evidence that the ductal phenotype of PDA might not reflect a strictly ductal origin. For example, whereas overexpression of activated Kras in acinar cells leads to tumor formation, tumors are not observed on Kras overexpression in ducts (10) (11) (12) . In addition, activation of endogenous Kras G12D in acinar-restricted precursor cells, via NestinCre, results in mPanIN formation similar to that observed with more widespread pancreatic Cre drivers such as Pdx1Cre and Ptf1a
Cre (14) . These previous experiments, however, do not address the question of whether mature acinar cells can give rise to PanINs, as all of them involved Kras G12D activation in utero or shortly after birth. Here, we have addressed both the contribution of Notch signaling to the initiation of pancreatic tumorigenesis, and the possibility that the acinar cell represents a source for precancerous lesions in the adult.
By using Pdx1CreERT to activate recombination in progenitor cells, we find that Notch dramatically sensitizes cells to Kras G12D -driven mPanIN initiation. In addition to mPanINs, we find metaplastic lesions induced by Kras G12D that may represent initial stages of acinar reprogramming to a ''pre-PanIN'' state. Furthermore, activation of Kras alone in adult acinar cells induces both metaplastic lesions and mPanINs, including highgrade mPanIN-2 and mPanIN-3, suggesting that acini can serve as a cell of origin for PDA. This process is dramatically enhanced when Notch is coactivated with Kras, producing rapid and widespread reprogramming of acinar cells to a duct-like phenotype, and apparently increased progression to high-grade lesions. Together, these results suggest that the observed up-regulation of Notch components in pancreatic cancer is not an epiphenomenon, but reflects a supporting role for Notch in Kras-induced reprogramming and transformation. Both positive and negative interactions between Notch and Ras have been described in other systems, and Notch can promote or inhibit tumorigenesis depending on cellular context (22) . In cultured human cells, Ras appears to activate Notch, and this activation is required for transformation (23) . In our model, by contrast, we find that Kras activation alone does not induce Notch target genes in the pancreas (Fig. S4) , suggesting that the pathways act convergently rather than linearly. Understanding the mechanism of this convergence may identify treatment targets for PDA.
Although several lines of evidence suggest that PanINs represent the early stages of human PDA (1), it remains a formal possibility that they instead represent ''dead ends'' in the genetic pathway that culminates in PDA. Similarly, although our data and those of others (13) suggest that metaplastic acini are the precursor to mPanIN lesions, we cannot yet rule out the possibility that overtly metaplastic structures, as described here, form independently of mPanINs. Further analysis of the kinetics of lesion formation, preferably by using a Cre driver that exhibits little or no TM-independent recombination, should indicate whether metaplasia clearly precedes mPanIN formation. Direct proofs of metaplasia-to-mPanIN and mPanIN-to-PDA progression will require more sophisticated lineage-tracing tools than currently exist.
Although our results suggest a model to unify diverse observations in the literature, we note some potential discrepancies. Although Rosa26 NIC activation in utero blocks acinar differentiation (18), we find that activation in mature acini is not sufficient for ductal reprogramming. In culture, however, Notch activation is both necessary and sufficient for acinar-ductal reprogramming (6) . These in vitro studies used adenoviral vectors to express activated Notch1, which may result in higher expression than our Rosa26 knock-in strategy; alternatively, placing acinar cells in culture may enhance endogenous Kras signaling. In addition, whereas we show that Kras G12D activation in acinar cells is sufficient for at least a small number of mPanINs to form, Guerra et al. (15) find that mPanINs do not form at all on acinar activation of an endogenous Kras G12V allele, unless the pancreas is subjected to caerulein-induced pancreatitis. This group used a tetracycline-regulated system to direct acinarspecific recombination, although ours is tamoxifen-regulated, but given that 6/11 TM-untreated Kras G12D ;ElaCreERT mice developed at least one mPanIN lesion in our study (versus 6/14 of TM-treated mice at the same ages), the use of tamoxifen cannot explain the discrepancy. A more plausible explanation is that differences in the targeted Kras alleles affect their expression or function, as Kras G12D has been shown to induce transformation in lung under circumstances in which Kras G12V appears less active (24, 25) .
Nonetheless, chronic pancreatitis is an important risk factor for human pancreatic cancer (1) , and the fact that caerulein pancreatitis sensitizes the mouse pancreas to activated Kras is likely relevant to our model. Caerulein pancreatitis promotes acinar-ductal metaplasia, and is associated with Notch pathway up-regulation (7, 16, 17) . As our study leaves open the question of how endogenous Notch becomes activated in mPanINs induced by Kras alone, further investigation of the links between pancreatitis, Notch activation and PanIN initiation are clearly warranted. Our work also leaves open the question of whether Notch signaling is necessary, as well as sufficient, for Kras G12D -induced mPanIN initiation and progression. Finally, as our study design focused on relatively short-term effects of Notch and Kras, we cannot determine whether the synergy between these pathways extends to the formation of fully invasive tumors. Aged Kras G12D ;Pdx1Cre mice do exhibit rare PDA (2), and we hypothesize that studies of older mice in our cohorts will reveal a contribution of Rosa26 NIC to invasive tumor formation.
A final issue left unresolved by our work is whether acinar cells represent the only cell of origin for mPanINs. In the uninjured pancreas, the Notch target gene Hes1 is expressed primarily by centroacinar cells (CACs), terminal cells of the duct network, and these have also been proposed as cells of origin for PanINs and PDA (1, 6) . Evidence for this derives from pancreas-specific deletion of the Pten tumor suppressor, which causes expansion and transformation of Hes1-expressing CACs, without acinar-ductal reprogramming (21) . Importantly, no ductal lesions formed when Pten was deleted exclusively in acinar cells (using the same ElaCre-ERT driver used here). Although PTEN loss-of-function mutations have not been reported in human pancreatic cancer, amplification of AKT2, encoding a kinase epistatic to PTEN, is found in a minority of PDAs (1). It is tempting to speculate that these tumors may arise from a different lineage, possibly through distinct mechanisms, than the acinar-to-ductal pathway identified here. Testing whether adult CAC or ductal cells are competent to form PanINs, on activation of Kras and/or Akt signaling, will require the development of temporally regulated Cre drivers specific to these compartments, an important priority for the field. In the meantime, our work allows us to conclude that acinar cells, via Notch-mediated ductal reprogramming, represent at least one potential major source for Krasinduced lesions. Future studies should elucidate the mechanism of, and requirement for, interaction between these critical signaling pathways.
Materials and Methods
Mice. Pdx1CreERT (19) , ElaCreERT (9, 20, 21) , Kras G12D (2) , and Rosa26 NIC (18) mice have been described previously, and were genotyped by PCR on tail biopsy DNA. As neither Kras G12D nor Rosa26 NIC is expressed in the absence of Cre, Cre-negative littermates from these crosses served as wild-type controls. Tamoxifen (TM) was dissolved in corn oil and administered by oral gavage. All experiments were carried out according to institutional guidelines.
Tissue Processing and Histology. After euthanasia, pancreata were dissected, cut into 5-6 fragments, and processed to frozen or paraffin sections as described (20) . PAS staining was performed according to the manufacturer's instructions (Sigma). Primary antibodies included rat anti-cytokeratin 19 1:50 (Developmental Studies Hybridoma Bank), sheep anti-amylase 1:2,500 (BioGenesis), rabbit anti-GFP 1:5,000 (Abcam), and guinea pig anti-Ptf1a 1:5,000 (gift of Dr. Jane Johnson, U.T. Southwestern), and secondary antibodies were purchased from Jackson Immunoresearch. Paraffin sections were subjected to high temperature antigen retrieval (Vector Unmasking Solution) before adding primary antibody. Vectastain reagents and Vector diaminobenzidine substrate were used for immunohistochemistry.
Lesion Scoring. Paraffin sections were cut from two independent dorsal and one ventral fragment of each pancreas. After H&E staining of a single section from each fragment, and photomicrography/photomerging (Adobe Photoshop), the area of the section was determined with ImageJ software (NIH). mPanIN lesions were then tallied under the microscope, and the PanIN initiation index was defined as the number of lesions per mm 2 , multiplied by 100, and averaged across the three sections scored for each mouse. Metaplastic lesions were scored similarly. In severely affected areas, lesions were scored as separate only if they appeared in anatomically distinct lobules. The same slides were subsequently evaluated, blindly, by a surgical pathologist (L.E.), who scored mPanIN lesions as 1A, 1B, 2, or 3 (4), and recorded the five highest-grade lesions per animal. The PanIN progression index was derived from this data as: 1ϫ (# mPanIN-1A/1B) ϩ 2ϫ (# mPanIN-2) ϩ 3ϫ (# mPanIN-3), resulting in scores from 0 (no mPanIN lesions at all) to 15 (five mPanIN-3 lesions found). Any score above 5 must reflect the presence of at least one high-grade mPanIN-2 or mPanIN-3 lesion.
RNA Isolation and Quantitative RT-PCR. RT-PCR was performed on ElaCreERT mice 7 days after TM treatment, at which point minimal gross changes were evident (Fig. 3E and data not shown) . RNA was isolated from approximately half of the dorsal pancreas by guanidinium isothiocyanate (26) . Realtime RT-PCR was performed on an ABI 7900HT instrument (Applied Biosystems), by using SYBR Green. Quantification was done by ⌬⌬Ct method, normalizing to the housekeeping gene Hprt1. Primers are listed in Table S1 , and were selected from the PrimerBank database (27) .
Statistics. All statistical analysis was performed with the R software package (28) . Comparisons of PanIN initiation indices were performed by Welch's t test (i.e., not assuming equal variances), with Holm's correction for multiple comparisons. Realtime PCR expression levels were compared to wildtype by ANOVA. PanIN progression indices were modeled as a function of PanIN initiation index (continuous) and Rosa26 NIC genotype (categorical), by using a general linear model with quasipoisson error distribution, and the contributions of the variables were evaluated by F-test.
